Adam Tomasi - Allakos President
| ALLK Stock | USD 0.89 0.02 2.30% |
President
Dr. Adam Tomasi, Ph.D. is Chief Financial Officer, Chief Operating Officer, Secretary of the Company. He has served as our Chief Operating Officer and Chief Financial Officer since April 2017 and as Secretary since November 2017. Dr. Tomasi is also on the board of directors of Attune Pharmaceuticals, a private biotechnology company. From August 2013 to January 2015, Dr. Tomasi served as Senior Vice President, Corporationrationrate Development of ZS Pharma, and from February 2015 to March 2017, he served as Chief Scientific Officer and Head of Corporationrationrate Development of ZS Pharma. Previously, Dr. Tomasi was a Principal at Alta Partners, where he was involved in the funding and development of notable medical technology and life science companies including Chemgenex, Excaliard, Lumena Pharmaceuticals, Achaogen, Immune Design, Allakos and ZS Pharma. Prior to joining Alta Partners, Dr. Tomasi was in the HarvardMIT Biomedical Enterprise Program where he completed internships as an equity analyst at Lehman Brothers and at MPM Capital. Dr. Tomasi also previously worked as a medicinal chemist with Gilead Sciences and Cytokinetics, where he helped create the cardiovascular drug CK1827452, which was licensed to Amgen since 2017.
| Age | 54 |
| Tenure | 7 years |
| Professional Marks | MBA |
| Address | 825 Industrial Road, San Carlos, CA, United States, 94070 |
| Phone | 650 597 5002 |
| Web | https://www.allakos.com |
Adam Tomasi Latest Insider Activity
Tracking and analyzing the buying and selling activities of Adam Tomasi against Allakos stock is an integral part of due diligence when investing in Allakos. Adam Tomasi insider activity provides valuable insight into whether Allakos is net buyers or sellers over its current business cycle. Note, Allakos insiders must abide by specific rules, including filing SEC forms every time they buy or sell Allakos'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Adam Tomasi over three months ago Disposition of 5369 shares by Adam Tomasi of Allakos at 4.54 subject to Rule 16b-3 | ||
Adam Tomasi over six months ago Disposition of 47392 shares by Adam Tomasi of Allakos at 1.44 subject to Rule 16b-3 | ||
Adam Tomasi over six months ago Acquisition by Adam Tomasi of 1200000 shares of Allakos subject to Rule 16b-3 | ||
Adam Tomasi over six months ago Acquisition by Adam Tomasi of 1200000 shares of Allakos at 1.25 subject to Rule 16b-3 |
Allakos Management Efficiency
The company has return on total asset (ROA) of (0.4875) % which means that it has lost $0.4875 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2168) %, meaning that it created substantial loss on money invested by shareholders. Allakos' management efficiency ratios could be used to measure how well Allakos manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.8. The value of Return On Capital Employed is expected to slide to -0.99. At this time, Allakos' Liabilities And Stockholders Equity is quite stable compared to the past year. Non Current Liabilities Other is expected to rise to about 55.5 M this year, although the value of Total Current Liabilities will most likely fall to about 21 M.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Erik Harris | Ultragenyx | 54 | |
| Jason Fontenot | Sangamo Therapeutics | 54 | |
| Christopher Murray | Blueprint Medicines Corp | 61 | |
| David Szekeres | Heron Therapeuti | 50 | |
| Thomas Ottoboni | Heron Therapeuti | 65 | |
| Sarah Cooley | Fate Therapeutics | N/A | |
| Fouad MD | Blueprint Medicines Corp | 55 | |
| Joseph Newell | Atara Biotherapeutics | 54 | |
| Leslie Robbins | CytomX Therapeutics | N/A | |
| Meredith Kaya | Apellis Pharmaceuticals | N/A | |
| Sean Ristine | Heron Therapeuti | 54 | |
| Stephen Betz | Crinetics Pharmaceuticals | 58 | |
| Juan Jaen | Arcus Biosciences | 66 | |
| Victoria Brown | Apellis Pharmaceuticals | 44 | |
| Michael Mathews | Heron Therapeuti | 61 | |
| Timothy Keutzer | Spero Therapeutics | 56 | |
Management Performance
| Return On Equity | -1.22 | ||||
| Return On Asset | -0.49 |
Allakos Leadership Team
Elected by the shareholders, the Allakos' board of directors comprises two types of representatives: Allakos inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Allakos. The board's role is to monitor Allakos' management team and ensure that shareholders' interests are well served. Allakos' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Allakos' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alan Chang, Director Analytics | ||
| Brad Youngblood, Head Research | ||
| Craig MD, Chief Officer | ||
| Henrik Rasmussen, Chief Medical Officer | ||
| Adam Tomasi, President | ||
| Baird III, Chief Officer | ||
| Mary Cromwell, Chief Officer | ||
| Robert Alexander, CEO, Director | ||
| MPH MD, Chief Officer |
Allakos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Allakos a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.22 | ||||
| Return On Asset | -0.49 | ||||
| Current Valuation | 26.18 M | ||||
| Shares Outstanding | 89.34 M | ||||
| Shares Owned By Insiders | 2.31 % | ||||
| Shares Owned By Institutions | 81.63 % | ||||
| Number Of Shares Shorted | 1.39 M | ||||
| Price To Earning | (21.26) X | ||||
| Price To Book | 0.61 X | ||||
| EBITDA | (189.91 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allakos. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Allakos Stock please use our How to buy in Allakos Stock guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allakos. If investors know Allakos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allakos listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.03) | Return On Assets (0.49) | Return On Equity (1.22) |
The market value of Allakos is measured differently than its book value, which is the value of Allakos that is recorded on the company's balance sheet. Investors also form their own opinion of Allakos' value that differs from its market value or its book value, called intrinsic value, which is Allakos' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allakos' market value can be influenced by many factors that don't directly affect Allakos' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allakos' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allakos is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allakos' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.